Shattuck Labs

Immunotherapy platform

Also second combo Clin1 ovarian cancer, Clin1 AML, MDS; undisclosed programs Clin0 oncology, autoimmune conditions

Shattuck Labs is developing treatments for cancer and autoimmune diseases by pioneering novel bi-functional fusion proteins. The tumor necrosis factor receptor (TNFr) with its involvement in immune regulation has been a popular therapeutic target. Using their Agonist Redirected Checkpoint (ARC) technology, Shattuck is creating molecules that both unlock the TNFr superfamily in a unique fashion while simultaneously blocking an immune checkpoint. As both targets on the molecule can be substituted, Shattuck is efficiently creating thousands of therapeutics which in turn can address multiple areas of high unmet clinical need. Currently, Shattuck’s portfolio includes over 400 bi-functional fusion proteins.